四受体激动剂在中期试验中显著减重且保留肌肉
Quadruple Agonist Reduced Weight Without Major Muscle Loss in Mid-Stage Trial
一项中期试验显示,口服四受体激动剂NA-931在13周内显著减重,最高剂量组体重减少13.8%,且保留了肌肉质量。与安慰剂组相比,该药耐受性良好,胃肠道副作用轻微。
— Once-daily oral agent also showed favorable tolerability
November 18, 2026 • 2 min read
NATIONAL HARBOR, Md. -- An investigational oral quadruple receptor agonist led to substantial weight loss with preservation of lean mass, a randomized phase II trial presented here showed.
By week 13, the two highest tested doses of NA-931 -- 150 mg and 120 mg -- led to reductions in mean body weight of 13.8% and 11.3%, respectively, compared with a reduction of 1.9% with placebo among adults with obesity or overweight and weight-related comorbidities (P=0.001 and P=0.002).
Participants receiving the two lowest doses -- 60 mg and 90 mg -- lost 5.5% and 8.7% of baseline body weight, respectively, according to Lloyd L. Tran, PhD, of developer Biomed Industries in San Jose, California, and colleagues.
The topline findings "support the potential of NA-931 as a first-in-class oral quadruple receptor agonist for weight loss, with promising efficacy and tolerability," Tran said at the ObesityWeek annual meeting, adding that the results also "suggest potential muscle preservation."
Using dual-energy x-ray absorptiometry (DEXA) measurements, which estimate lean soft tissue, including skeletal muscle, organs, and water (though changes do not directly establish shifts in muscle function), lean mass decreased by 1.7% over 13 weeks among participants treated with NA-931.
For context, longer-duration trials of the GLP-1 agonist semaglutide (Wegovy) over 68 weeks and the dual GLP-1/GIP agonist tirzepatide (Zepbound) over 72 weeks reported reductions in lean mass of 13.2% and 10.9%, respectively. According to a 2025 meta-analysis of 22 randomized trials of semaglutide and tirzepatide, including 2,258 patients, lean mass reductions made up roughly 25% of total weight lost.
"We believe we are entering an era of post-GLP-1 where there is a need for sustainable obesity management" that pairs meaningful weight loss with preserved muscle strength, Tran said. That preservation is particularly critical for older adults, he noted, as muscle mass naturally declines by roughly 3% to 8% per decade after age 30 and accelerates after age 60.
NA-931 is a small molecule that targets four receptors: insulin-like growth factor-1 (IGF-1), GLP-1, GIP, and glucagon. Because the compound readily crosses the blood-brain barrier, only a low dose is needed for efficacy, Tran explained, which may contribute to its favorable tolerability profile.
In the 150-mg NA-931 group, rates of gastrointestinal adverse events -- a common side effect of GLP-1-based therapies -- were only slightly higher than with placebo, including nausea (12.5% vs 10.3%; all cases mild), vomiting (8.3% vs 6.9%), and diarrhea (8.3% vs 6.9%). No participants in the 150-mg arm discontinued treatment.
By comparison, pivotal trials of semaglutide and tirzepatide reported nausea in 44.2% (vs 17.4% on placebo) and 24.6% to 33.3% (vs 9.5% on placebo) of participants, respectively.
This multicenter, double-blind trial enrolled 125 adults with obesity or overweight and weight-related comorbidities. Participants were randomized to receive once-daily oral NA-931 at 60 mg, 90 mg, 120 mg, or 150 mg, or placebo. Mean participant age across the groups ranged from 41.9 to 46.7 years. Most were female (62.5% to 66.6%) and white (62.5% to 68.9%). Mean baseline weight was 212 to 220.9 lb and mean body mass index was 34.4 to 37.8.
Patients in the 150-mg group also saw a modest reduction in HbA1c levels (-0.2%).
Tran said Biomed Industries is advancing NA-931 into phase III clinical testing.
来源:MedPage Today · medpagetoday.com